Release
📈 Stocks
Provectus Biopharmaceuticals Reports 95.5% Response Rate in Oral Cancer Trial
(just now)
Provectus Biopharmaceuticals shares rally as Phase 2 trial data for PRV111 shows a 95.5% pathologic complete response rate in early-stage oral cancer…